The study, led by Dr. Lucas Moreno and University of Birmingham shows that the combined administration of chemotherapy and immunotherapy with the antibody dinutuximab beta achieves a better treatment response.

The donation will support a project investigating new therapeutic approaches in pediatric brain tumors

The €15,000 donation will boost research into this very rare type of childhood cancer.

The association has donated €15,088 to the Childhood Cancer and Blood Disorders group at VHIR to improve the treatment of rhabdomyosarcoma.

The funds raised will contribute to ensuring the continuity of the pediatric brain tumor research line developed by the Vall d’Hebron research teams.

2025 has been an active year with the participation of RADeep members at the Data Access Committee at Vall d’Hebron and the presentation of abstracts at the 67th ASH Annual Meeting and Exposition.

Since 2019, Pulseras Candela has been collaborating with the Childhood Cancer and Hematological Diseases group at VHIR on the project “New Therapeutic Approaches for the Treatment of Pediatric Ependymoma.”

The session has helped bring the public an up-to-date perspective on diagnosis, treatments, and the research lines that are transforming the future of patients.

The donation will boost several lines of research to advance liquid biopsy in pediatric sarcomas and brain tumors.

The project aims to improve prevention, diagnosis, and treatment through computational biomedicine, innovative therapies, and the transfer of knowledge into clinical practice.

The Lancet Neurology publishes the new criteria, the result of a global expert consensus led by Dr Xavier Montalban.

The annual event offered a space for dialogue between the scientific community and society on how to address the future of ageing through research and innovation.

The second edition of the AI ​​Day served to share knowledge, reflect and chart the future of artificial intelligence applied to research and health.

The Barcelona Risk Score is a flexible, generalisable clinical tool that will play a key role in selecting the most effective treatment for each person with multiple sclerosis

The study analyzes the impact of COVID-19 on people with rare red blood cell disorders, identifying risk factors for severe forms of the disease.

Docetaxel, carried by Soluplus, proved to be the most effective and least toxic combination to cross the blood-brain barrier and attack the tumour directly.

The study, led by Vall d'Hebron, is the first in Spain to analyse the relationship between pregnancy complications and the risk of long-term cardiovascular diseases.

The consensus document is the result of multidisciplinary work that takes into account the risks associated with all stages of women's lives and the differences compared to men.

Based on the study led by VHIR, a clinical trial has been approved for patients with locally advanced pancreatic cancer.

Vall d'Hebron participates in a project to develop innovative microsampling technology, making blood collection more accessible and patient-centered.

The study, which involved Vall d'Hebron, developed an action plan to efficiently allocate resources to patients most at risk of suffering this complication.

The association, once again, has shown its commitment to oncological research with a donation of €19,197 to the Cancer and Hematological Diseases Group for Children at VHIR.

In light of this evidence, hospitals such as Vall d'Hebron have already started to include warnings about environmental pollution in their hospital discharge plans after a myocardial infarction.

Researchers from all over Europe gathered to kick off the SPM4.0 project, an innovative Marie Curie Skłodowska (MSCA-DN) doctoral network that promotes the development of autonomous Scanning Probe Microscopy with AI.